Published in J Thorac Oncol on June 01, 2014
Dasatinib in Advanced Squamous Cell Lung Cancer | NCT01491633
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. ACS Med Chem Lett (2015) 0.80
DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. Oncotarget (2016) 0.75
Lung Cancer Biomarkers. Hematol Oncol Clin North Am (2017) 0.75
Advances in mass spectrometry based strategies to study receptor tyrosine kinases. IUCrJ (2017) 0.75
Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer. Am J Transl Res (2016) 0.75
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol (2007) 6.56
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell (2003) 4.56
Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell (2004) 4.34
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol (2010) 2.79
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res (2011) 2.01
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol (2008) 2.01
Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev (2012) 1.96
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res (2012) 1.95
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One (2012) 1.82
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res (2008) 1.74
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol (2012) 1.61
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer (2007) 1.53
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A (2008) 1.51
Receptor tyrosine kinase coactivation networks in cancer. Cancer Res (2010) 1.46
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A (2000) 1.37
Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem (2013) 1.27
Mouse models for lung cancer. Mol Oncol (2013) 1.18
Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol (2012) 1.10
Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem J (2013) 1.08
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol (2013) 1.08
BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol (2011) 1.05
Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem (2005) 1.04
Discoidin domain receptors promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation. PLoS One (2012) 1.04
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer (2013) 1.00
Discoipyrroles A-D: isolation, structure determination, and synthesis of potent migration inhibitors from Bacillus hunanensis. J Am Chem Soc (2013) 0.99
Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal (2013) 0.94
Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem (2011) 0.93
Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer (2012) 0.91
Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut (2011) 0.90
Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell Adh Migr (2012) 0.87
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol (2013) 0.87
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther (2013) 0.87
A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis. J Pathol (2014) 0.86
Actinomycin D identified as an inhibitor of discoidin domain receptor 2 interaction with collagen through an insect cell based screening of a drug compound library. Biol Pharm Bull (2009) 0.84
DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients. Oncol Lett (2012) 0.83
β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model. Sci Rep (2012) 0.82
Phosphoproteomic studies of receptor tyrosine kinases: future perspectives. Mol Biosyst (2011) 0.82
Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. J Thorac Oncol (2012) 0.76
14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature (2007) 2.98
Receptor tyrosine kinase coactivation networks in cancer. Cancer Res (2010) 1.46
Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem J (2013) 1.08
Discoidin domain receptors promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation. PLoS One (2012) 1.04
The pathobiology of collagens in glioma. Mol Cancer Res (2013) 0.99
An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol Biosyst (2008) 0.92
Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell Adh Migr (2012) 0.87
Discoidin domain receptors: a proteomic portrait. Cell Mol Life Sci (2014) 0.84
Cancer: Melanoma troops massed. Nature (2009) 0.81